The Future Of US FDA’s Institutional Memory
Upcoming retirement of Janet Woodcock will mean loss of one of agency's FDA’s most experienced and influential drug regulators. However, CDER still has plenty of long-tenured staff peppered across all its key functions.
You may also be interested in...
The FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues told the Pink Sheet.
The elevation of the US FDA’s top drug regulator, Janet Woodcock, to oversee COVID-19 response efforts is being framed a temporary step as part of the crisis response. But it is also a try-out for the most significant leadership transition in drug regulation in the US in a generation.
Aggressive staffing goals for FDA’s gene and cell therapy review group might not be fully achieved – but the head of CBER believes the new organization is on track to deliver on his high expectations going forward.